Enhancing glioblastoma treatment by targeting tumor-supporting immune cells
Improving glioma radiotherapy by theragnostic targeting of tumor-supporting macrophages
['FUNDING_R01'] · PURDUE UNIVERSITY · NIH-11056734
This study is looking at a new way to make radiation therapy work better for people with glioblastoma by using a safe, approved drug to target certain immune cells in the tumor, hoping to help the treatment be more effective for both newly diagnosed and returning patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PURDUE UNIVERSITY (nih funded) |
| Locations | 1 site (WEST LAFAYETTE, UNITED STATES) |
| Trial ID | NIH-11056734 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to improve radiotherapy for glioblastoma patients by targeting tumor-associated macrophages (TAMs) with an FDA-approved drug called ferumoxytol. The goal is to understand how this targeting can enhance the effectiveness of radiotherapy, which is often limited by the tumor's ability to resist treatment. By reducing the number of immunosuppressive TAMs, the researchers aim to make glioma cells more sensitive to radiation and boost the body's anti-tumor immune response. The study will focus on both newly diagnosed and recurrent glioblastoma patients to evaluate the potential benefits of this combined treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, whether newly diagnosed or experiencing a recurrence.
Not a fit: Patients with other types of brain tumors or those who do not have glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting tumor-associated macrophages to enhance cancer treatment, suggesting that this approach could be effective for glioblastoma as well.
Where this research is happening
WEST LAFAYETTE, UNITED STATES
- PURDUE UNIVERSITY — WEST LAFAYETTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCARPELLI, MATTHEW — PURDUE UNIVERSITY
- Study coordinator: SCARPELLI, MATTHEW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer, burden of disease, cancer microenvironment, Cancers